司坦唑醇联合环孢素A治疗慢性再生障碍性贫血的效果分析  

Effect of stanozolol combined with cyclosporine A on chronic aplastic anemia

作　　者：郭芳[1] 许肖冰 赵艳秋[1] Guo Fang;Xu Xiaobing;Zhao Yanqiu(Department of Hematology,Anyang District Hospital of Puyang,Anyang 455000,China)

机构地区：[1]濮阳市安阳地区医院血液科,安阳455000

出　　处：《中国实用医刊》2023年第6期104-107,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨司坦唑醇联合环孢素A治疗慢性再生障碍性贫血的应用价值。方法回顾性分析2016年8月至2021年10月濮阳市安阳地区医院收治的62例慢性再生障碍性贫血患者的临床资料。将纳入患者以随机数字表法为观察组与对照组,每组31例。对照组采用司坦唑醇,观察组在对照组基础上加用环孢素A。比较两组临床疗效、T淋巴细胞亚群水平、血红蛋白(Hb)水平、白细胞计数(WBC)、辅助性T细胞(Th细胞)水平及不良反应发生率。结果观察组总有效率(96.77%,30/31)高于对照组(74.19%,23/31),P<0.05;治疗后,观察组CD4^(+)、CD3^(+)水平高于对照组(P<0.05);治疗后,观察组Hb、WBC水平高于对照组(P<0.05),Th1/Th2水平低于对照组(P<0.05)。观察组不良反应发生率(6.45%,2/31)与对照组(9.68%,3/31)比较差异未见统计学意义(P>0.05)。结论司坦唑醇联合环孢素A治疗慢性再生障碍性贫血可提高临床疗效,调节Th1/Th2表达,改善免疫功能,促进外周血指标恢复正常,并具有用药安全性。Objective To investigate the application value of stanozolol combined with cyclosporine A in the treatment of chronic aplastic anemia.Methods The clinical data of 62 patients with chronic aplastic anemia treated in Anyang District Hospital of Puyang from August 2016 to October 2021 were retrospectively analyzed,and they were divided into observation group and control group according to random number table method,with 31 cases in each group.The control group was given stanozolol,while the observation group was given cyclosporine A based on the treatment of the control group.The clinical efficacy,T lymphocyte subgroup level,hemoglobin(Hb),white blood cell(WBC),helper T cells(Th cells)level and adverse reaction rate were compared between the two groups.Results The total effective rate of the observation group(96.77%,30/31)was higher than that of the control group(74.19%,23/31),P<0.05.After treatment,the levels of cluster of differention 4^(+)(CD4^(+))and cluster of differention 3^(+)(CD3^(+))in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of Hb and WBC in the observation group were higher than those in the control group(P<0.05).The levels of Th1/Th2 in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group(6.45%,2/31)and the control group(9.68%,3/31),P>0.05.Conclusions Stanozolol combined with cyclosporine A in the treatment of chronic aplastic anemia can improve the clinical efficacy,regulate Th1/Th2 expression,improve immune function,and promote the recovery of peripheral blood indicators,with drug safety.

关 键 词：再生障碍性贫血 司坦唑醇 环孢素A 

分 类 号：R556.5[医药卫生—血液循环系统疾病]